These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35202851)

  • 1. Design, synthesis and anticancer evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 1,8-naphthyridine-3-carboxamide moiety as novel multi-target TKIs.
    Chen P; Zhao Y; Zhang J; Duan Y; Dai J; He J; Wang X; Chen X; Chen P; Zhao W; Wang X; Zhuang Z; Yang D; Liang G; Tang Q
    Bioorg Chem; 2022 Apr; 121():105672. PubMed ID: 35202851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 1,8-naphthyridin-2-one moiety.
    Tang Q; Duan Y; Xiong H; Chen T; Xiao Z; Wang L; Xiao Y; Huang S; Xiong Y; Zhu W; Gong P; Zheng P
    Eur J Med Chem; 2018 Oct; 158():201-213. PubMed ID: 30216852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 2-oxo-4-chloro-1,2-dihydroquinoline-3-carboxamide moiety.
    Tang Q; Zhai X; Tu Y; Wang P; Wang L; Wu C; Wang W; Xie H; Gong P; Zheng P
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1794-8. PubMed ID: 26944614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis and Biological Evaluation of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing Pyridazinone Moiety as c-Met Inhibitors.
    Liu X; Kou J; Xiao Z; Tian F; Hu J; Zheng P; Zhu W
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29949931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
    Zhou S; Ren J; Liu M; Ren L; Liu Y; Gong P
    Bioorg Chem; 2014 Dec; 57():30-42. PubMed ID: 25173590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
    Liu Z; Wang R; Guo R; Hu J; Li R; Zhao Y; Gong P
    Bioorg Med Chem; 2014 Jul; 22(14):3642-53. PubMed ID: 24882675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Synthesis of Novel 4-Phenoxyquinolines Bearing 3-Hydrosulfonylacrylamido or 1H-Imidazole-4-carboxamido Scaffolds as c-Met Kinase Inhibitors.
    Wang J; Xie L; Wang Y; Wang X; Xi S; Zeng T; Gong P; Zhai X
    Arch Pharm (Weinheim); 2017 Feb; 350(2):. PubMed ID: 28133784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors.
    Liu J; Yang D; Yang X; Nie M; Wu G; Wang Z; Li W; Liu Y; Gong P
    Bioorg Med Chem; 2017 Aug; 25(16):4475-4486. PubMed ID: 28716639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives Containing Benzo[d]thiazole-2-yl Urea as c-Met Kinase Inhibitors.
    Lei H; Hu G; Wang Y; Han P; Liu Z; Zhao Y; Gong P
    Arch Pharm (Weinheim); 2016 Aug; 349(8):651-61. PubMed ID: 27283017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
    Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
    Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
    Tang Q; Zhao Y; Du X; Chong L; Gong P; Guo C
    Eur J Med Chem; 2013 Nov; 69():77-89. PubMed ID: 24012712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
    Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
    Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
    Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors.
    Wang L; Xu S; Chen X; Liu X; Duan Y; Kong D; Zhao D; Zheng P; Tang Q; Zhu W
    Bioorg Med Chem; 2018 Jan; 26(1):245-256. PubMed ID: 29203143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
    Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
    Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors.
    Liu J; Nie M; Wang Y; Hu J; Zhang F; Gao Y; Liu Y; Gong P
    Eur J Med Chem; 2016 Nov; 123():431-446. PubMed ID: 27490023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
    Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
    Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
    Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y
    Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.